Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7106656 | 0.81 | — | — | |
| SCHEMBL7156687 | 0.81 | — | — | |
| SCHEMBL27727627 | 0.73 | CA1 (0.31) | CA1CA2CA7 | |
| SCHEMBL5178505 | 0.73 | TSHR (0.35) | — | |
| Hydrochloric Acid SCHEMBL27723402 | 0.71 | — | — | |
| SCHEMBL28238557 | 0.69 | CA1 (0.31) | CA1CA2CA7 | |
| SCHEMBL7217636 | 0.68 | — | — | |
| SCHEMBL87984 | 0.67 | TSHR (0.32) | — | |
| SCHEMBL8979350 | 0.66 | ALDH1A1 (0.41) | — | |
| SCHEMBL579422 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240084307-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2024-03-14 | — | — | US | disclosed |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA INC (US) | 2024-02-29 | — | — | US | disclosed |
| CN-114874075-B | Method for refining high-purity allyl alcohol from byproducts of polyalcohol allyl ether | 浙江皇马科技股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| EP-4259799-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | Civi Biopharma, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11739332-B2 | Antisense oligomers targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2023-08-29 | — | — | US | disclosed |
| WO-2022125913-A9 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20220213476-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2022-07-07 | — | — | US | disclosed |
| WO-2022125913-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220025376-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2022-01-27 | — | — | US | disclosed |
| EP-3914232-A1 | LIPID VESICLE FOR ORAL DRUG DELIVERY | F. Hoffmann-La Roche AG (CH) | 2021-12-01 | — | — | EP | disclosed |
| CN-1049817-C | Percutaneously absorbable eperisone or tolperisone preparation | SEKISUI CHEMICAL CO LTD (JP) | 2000-03-01 | — | — | CN | disclosed |
| EP-0454089-B1 | Percutaneously absorbable eperisone or tolperisone preparation | SEIKISUI CHEMICAL CO LTD (JP) | 1994-08-17 | — | — | EP | disclosed |
| US-5252588-A | Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation | SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1993-10-12 | — | — | US | disclosed |
| CN-1056055-A | Eperisone and mydocalm preparation that percutaneous absorbs | SEIKISUI CHEMICAL CO LTD (JP) | 1991-11-13 | — | — | CN | disclosed |
| EP-0454089-A1 | Percutaneously absorbable eperisone or tolperisone preparation | SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1991-10-30 | — | — | EP | disclosed |
| US-4880455-A | MULTILAYER COATINGS OF UNSATURATED OILS CROSSLINKED WITH DIUNSATURATED MONOMERS | HAIFA CHEMICALS LIMITED (IL) | 1989-11-14 | — | — | US | disclosed |
| US-4533540-A | VINYLPYRROLIDONE COPOLYMER PROVIDES STABILITY | FOREST LABORATORIES, INC. (US) | 1985-08-06 | — | — | US | disclosed |
| US-4482534-A | VINYLPYRROLIDONE POLYMER, SUSTAINED RELEASE, TRANSDERMAL ADMINISTEING | FOREST LABORATORIES, INC. (US) | 1984-11-13 | — | — | US | disclosed |
| EP-0054279-B1 | COMPOSITION WITH SUSTAINED RELEASE OF NITROGLYCERINE, AND METHOD OF PREPARING IT | Forest Laboratories, Inc. (US) | 1984-07-25 | — | — | EP | disclosed |
| EP-0054279-A2 | Composition with sustained release of nitroglycerine, and method of preparing it | Forest Laboratories, Inc. (US) | 1982-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | PCSK9, SCD5, PCSK7 | CA1 2704/4885CA2 1578/4885CA7 1028/4885 |
| US-20220213476-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | PCSK9, SCD5, PCSK7 | CA1 2704/4885CA2 1578/4885CA7 1028/4885 |
| US-11739332-B2 | Antisense oligomers targeting PCSK9 | PCSK9, PCSK7, PCSK6 | CA1 4788/4885CA2 4756/4885CA7 4601/4885 |
| US-20220025376-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | PCSK9, PCSK7, PCSK6 | CA1 4788/4885CA2 4756/4885CA7 4601/4885 |
| US-20240084307-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | PCSK9, PCSK7, PCSK6 | CA1 4788/4885CA2 4756/4885CA7 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.